A Mechanistic Systems Pharmacology Model for Prediction of LDL Cholesterol Lowering by PCSK9 Antagonism in Human Dyslipidemic Populations

• Egile Nagusiak: K Gadkar (Egilea), N Budha (Egilea), A Baruch (Egilea), J D Davis (Egilea), P Fielder (Egilea), S Ramanujan (Egilea)
• Formatua: Liburua
• Argitaratua: Wiley, 2014-11-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

PCSK9 is a promising target for the treatment of hyperlipidemia and cardiovascular disease. A Quantitative Systems Pharmacology model of the mechanisms of action of statin and anti‐PCSK9 therapies was developed to predict low density lipoprotein (LDL) changes in response to anti‐PCSK9 mAb for differ...